Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04717414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04717414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 25, 2021
Completion date
August 18, 2032
Enrollment
313 (actual)
Sites
185

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, myelofibrosis, myeloproliferative disorders, post-polycythemia vera myelofibrosis, primary myelofibrosis